Effect of host defenses on Clostridium difficile toxin-induced intestinal barrier injury

Journal of Trauma and Acute Care Surgery

Volumn 74, Issue 4, 2013, Pages 983-990

  Olson, Alicia ^a   Diebel, Lawrence N ^a   Liberati, David M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile toxin A; HT29 MTX cells; mucin; SIgA

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; INTERLEUKIN 6; INTERLEUKIN 8; PROTEINASE; SECRETORY COMPONENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL STRAIN HT29; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HOST RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; INTESTINE EPITHELIUM CELL; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PRIORITY JOURNAL;

BACTERIAL PROTEINS; BACTERIAL TOXINS; BIOLOGICAL TRANSPORT; CLOSTRIDIUM DIFFICILE; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HT29 CELLS; HUMANS; INTESTINAL MUCOSA; SECRETORY COMPONENT;

EID: 84876160855     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e3182858477     Document Type: Article

References (25)

1. Gould CV, McDonald LC. Bench-to-bedside review: Clostridium difficile colitis. Crit Care. 2008;12:203-213.
2. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011; 365(18):1693-1703.
3. Kachrimanidou M, Malisiovas N. Clostridium difficile infection: a comprehensive review. CRC Crit Rev Microbiol. 2011;37(3):178-187.
4. Sun X, Savidge T, Feng H. The enterotoxicity of Clostridium difficile toxins. Toxins. 2010;2:1848-1880.
5. Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastro-enterol. 2012;28:1-9.
6. Dudukgian H, Sie E, Gonzalez-Ruiz C, Etzioni DA, Kaiser AM. C. diff colitisVpredictors of fatal outcome. J Gastrointest Surg. 2010;14:315-322.
7. Greenstein AJ, Byrn JC, Zhang LP, Swedish KA, Jahn AE, Divino CM. Risk factors for the development of fulminant Clostridium difficile colitis. Surgery. 2008;143(5):623-629.
8. Butala P, Divino CM. Surgical aspects of fulminant Clostridium difficile colitis. Am J Surgery. 2010;200:131-135.
9. Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, Alam HB, DeMoya MA, Velmahos GC. Fulminant Clostridium difficile colitis. Patterns of care and predictors of mortality. Arch Surg. 2009;144(5): 433-439.
10. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons RL. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235(2):363-372.
11. Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci. 2011;56(1):19-26.
12. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clos-tridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390-397.
13. McGuckin MA, Linden SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. Nature Reviews/Microbiology. 2011;9:265-278.
14. Hansson GC. Role of mucus layers in gut infection and inflammation. Curr Opin Microbiol. 2012;15:57-62.
15. Mantis NJ, Rol N, Corthesy B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Immunology. 2011;4:603-611.
16. Lesuffleur T, Porchet N, Aubert JP, Swallow D, Gum JR, Kim YS, Real FX, Zweibaum A. Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT-29 cell subpopulations. J Cell Sci. 1993;106:771-783.
17. Feltis BA, Wiesner SM, Kim AS, Erlandsen SL, Lyerly DL, Wilkins TD, Wells CL. Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes. Shock. 2000;60:629-634.
18. Kelly CP, Kyne LR. The host immune response to Clostridium difficile. J Med Microbiol. 2011;60:1070-1079.
19. Lamont JT. How bacterial enterotoxins work: insights from in vivo studies. Trans Am Clin Climatol Assoc. 2002;113:167-181.
20. Glenn GM, Francis DH, Danielsen EM. Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines. Infect Immun. 2009;77(12):5206-5215.
21. Nustrat A, von Eichel-Streiber C, Turner JR, Verkade P, Madara JL, Parkos CA. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun. 2001;69(3):1329-1336.
22. Hussack G, Tanha J. Toxin-specific antibodies for the treatment of Clos-tridium difficile: Current status and future perspectives. Toxins. 2010;2: 998-1018.
23. Giannasca PJ, Warny M. Active and passive immunization against Clos-tridium difficile diarrhea and colitis. Vaccine. 2004;22:848-856.
24. Stubbe H, Berdoz J, Kraehenbuhl JP, Corthesy B. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging T84 monolayers. J Immunology. 2000;164:1952-1960.
25. Gibson PR, Muir JG. Reinforcing the mucus: a new therapeutic approach for ulcerative colitis? Gut. 2005;54:900-903.